---
title: "파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를 2,788억원에서 5,133억원으로 상향했다. — 하나증권 — DecisionGateway"
description: "statement by 하나증권, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8"
meta:
  "og:description": "statement by 하나증권, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를 2,788억원에서 5,133억원으로 상향했다. — 하나증권 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를 2,788억원에서 5,133억원으로 상향했다.**

A statement by [**하나증권**](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *파브리병 후보물질 HM15421 기술이전 가치 1,404억원 반영*

hanaresearchPublished 2026-11-08 [ Read source](https://t.me/hanaresearch/20910)

[**하나증권 dossier **](https://dgw.tmarket.io/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

## **Related claims**

[**에피노페그듀타이드 2b상 결과는 11/5 AASLD 2026에서 공개됐다.**하나증권 · statement](https://dgw.tmarket.io/claims/01a1ceb7-cfdb-716a-bbc3-96c46fa06956) [**HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f715-7150-a782-62a08f93decd) [**HanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f723-73df-9e13-66f79ab9d480) [**Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6fe-7e21-bace-a811a7b3596d) [**에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.**하나증권 · statement](https://dgw.tmarket.io/claims/01a1ceb7-cff0-71a7-a8d3-66029cb5c55b) [**에이티넘인베스트먼트가 이노보테라퓨틱스에 150억을 투자해 7년 만에 결실을 봤다.**kgrowth · statement](https://dgw.tmarket.io/claims/01a1d42f-1e29-7c80-bc01-7b4f6a33fcec)

## **More claims by 하나증권**

[**The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b231-7d52-805c-3f604b6a5af0) [**The U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b21a-7518-829b-60cdc773571a) [**This report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b20e-78ef-8998-71366dda0c35) [**An approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b203-77a2-bb21-b5002bb38a65) [**Ahead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.**statement](https://dgw.tmarket.io/claims/01a1d4ae-b1f8-780c-a428-efe4735941fd)

[All claims by 하나증권](https://dgw.tmarket.io/claims?claimant_id=01a1cea2-176c-7cf2-87ea-9ed64a8130ca)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8#webpage","@type":"WebPage","description":"statement by 하나증권, recorded recently — verbatim quote and source citation.","name":"파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를 2,788억원에서 5,133억원으로 상향했다. — 하나증권 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-08","isBasedOn":"https://t.me/hanaresearch/20910","text":"파브리병 후보물질 HM15421 기술이전 가치 1,404억원 반영","url":"/claims/01a1ceb7-d036-76fd-be61-65f8b5a4c8f8","spokenByCharacter":{"@type":"Person","name":"하나증권","@id":"/actors/01a1cea2-176c-7cf2-87ea-9ed64a8130ca"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.